STAT

Opinion: State drug importation programs will work with the FDA, not outside of it

State programs can use the global pharmaceutical supply chain to relieve the sometimes crushing financial burden of drug treatments — at least until we have an effective national approach to…

The safety of the supply chain for pharmaceuticals in the United States must be built with solid links. That hasn’t always been the case, which is why the (DQSA) was signed into law in 2013. Part of that law () mandates the development of a national “track-and-trace” electronic system that documents a drug’s distribution path from the manufacturing plant to the pharmacy counter. It facilitates detection and removal of potentially dangerous drugs from the drug supply chain. This system, which will be fully implemented in the next few years, will extend to drugs manufactured outside in the U.S. in FDA-registered facilities.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly Buying A Plant, A Pfizer Antibiotic, And More
Eli Lilly agreed to acquire a manufacturing facility in Wisconsin from Nexus Pharmaceuticals to produce injectable medicines amid shortages of Mounjaro and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.

Related Books & Audiobooks